Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2023 08:30 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity

BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...
April 09, 2019 08:00 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Appointment of Elizabeth O’Farrell to its Board of Directors

ATLANTA and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and...
March 19, 2019 08:00 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson’s Disease

ATLANTA and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and...
March 05, 2019 08:00 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Appoints Leading Experts in Parkinson’s Disease to its Scientific Advisory Board

ATLANTA and BOSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and...
February 26, 2019 08:00 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinson’s Disease

ATLANTA and BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for treatment of neurological infections and...